| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2025―Jun―09 |
Infliximab Pharmacokinetics, Dosing, and Response in Hospitalized Patients with COVID-19 Pneumonia: A Secondary Analysis of a Multinational Randomized Clinical Trial (ACTIV-1 IM) |
Stephen J. Balevic, Daniel Gonzalez, P. Brian Smith, William G. Powderly, Andreas Schmid, Ashley Kang, Matthew W. McCarthy, Linda K. Shaw, Christopher J. Lindsell, Sam Bozzette, Richard M. W. Hoetelmans, Christoph P. Hornik, Daniel K. Benjamin Jr |
| 2 |
[GO] |
2023―Nov―30 |
Infliximab Concentrations in Participants with Moderate to Severe COVID-19 |
Stephen J. Balevic, Dima Dandachi, Danielle Dixon, Richard M.W. Hoetelmans, Sam Bozzette, Matthew W. McCarthy |
| 3 |
[GO] |
2023―Sep―26 |
Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID-19 |
Ravi Shankar P. Singh, Robert R. LaBadie, Sima S. Toussi, Haihong Shi, Jolene Kay Berg, Joel M. Neutel, Sudeepta Aggarwal |
| 4 |
[GO] |
2023―Mai―01 |
Ibuprofen in the Management of Viral Infections: The Lesson of COVID-19 for Its Use in Clinical Setting |
Gianmarco Marcianò, Lucia Muraca, Vincenzo Rania, Luca Gallelli |
| 5 |
[GO] |
2023―Apr―12 |
Evaluation of drug-drug interactions of ensitrelvir, a SARS-CoV-2 3CL protease inhibitor, with transporter substrates based on in vitro and a clinical study |
Ryosuke Shimizu, Takanobu Matsuzaki, Ryoko Oka, Takuhiro Sonoyama, Takahiro Fukuhara, Aya Kuwata, Yumiko Matsuo, Ryuji Kubota |
| 6 |
[GO] |
2022―Dez―15 |
Embracing Uncertainties Over the Evidence of New Oral Antivirals for COVID-19: Challenges in Pharmacoepidemiologic Research |
Renato Ferreira da Silva, Ana Marta Silva, Manuela Morato, Inês Ribeiro-Vaz, Jorge Junqueira Polónia |
| 7 |
[GO] |
2022―Nov―18 |
Ivermectin role in the prevention of COVID-19: A systematic review and meta-analysis |
Gong-Yi Hu, Chun-An Liang, Pei-Chin Lin, Chih-Yang Lin |
| 8 |
[GO] |
2022―Sep―26 |
A potential drug interaction between Favipiravir and Warfarin in patients with COVID-19: A real-world observational study |
Konkanok Wattana, Suriyon Uitrakul, Nattapol Leesakulpisut, Pirawan Khunkit |
| 9 |
[GO] |
2022―Sep―23 |
Considerations and Challenges in the Remdesivir Covid-19 Pediatric Development Program |
Kirk Chan-Tack, Mario Sampson, Justin Earp, Vikram Arya, Lynne Yao, John Alexander, Ethan Hausman, Yodit Belew, Debra Birnkrant, Kimberly Struble |
| 10 |
[GO] |
2022―Jun―03 |
Population Pharmacokinetics of Hydroxychloroquine Sulphate in Healthcare Workers Given for Prophylaxis Against Corona Virus Disease 2019 (COVID-19) in India |
Jeffrey Pradeep Raj, Nithya Jaideep Gogtay, Avaneesh Pandey, Ashish Kumar Kakkar, Nusrat Shafiq Khan, Mekala Padmaja, Usharani Pingali, Arun Prasath Raju, Surulivelrajan Mallayasamy, Nilima Arun Kshirsagar |
| 11 |
[GO] |
2022―Mai―06 |
New Variants of SARS-CoV-2 and Next Generation of COVID-19 Treatments |
Sajad Khiali, Taher Entezari-Maleki |
| 12 |
[GO] |
2022―Apr―23 |
Physiologically-Based Pharmacokinetic Modeling Approaches for Patients with SARS-CoV-2 Infection: A Case Study with Imatinib |
Jeffry Adiwidjaja, Josephine A Adattini, Alan V Boddy, Andrew J. McLachlan |
| 13 |
[GO] |
2022―Feb―11 |
Hypertensive Crisis following COVID-19 Vaccination |
Elnaz Khani, Taher Entezari-Maleki |
| 14 |
[GO] |
2021―Dez―18 |
Association between baseline use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers and death among patients tested for COVID-19 |
Sarah A. Thomas, Michael Puskarich, Michael S. Pulia, Andrew C. Meltzer, Carlos A. Camargo, D. Mark Courtney, Kristen E. Nordenholz, Jeffrey A. Kline, Christopher Kabrhel |
| 15 |
[GO] |
2021―Nov―21 |
Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance |
Elettra Fallani, Fabio Cevenini, Pietro Enea Lazzerini, Annalisa Verdini, Simona Saponara |
| 16 |
[GO] |
2021―Nov―18 |
Clearance of lormetazepam, midazolam, and their conjugated metabolites by continuous venovenous hemofiltration during prolonged sedation in critically ill patients with COVID-19-associated acute respiratory distress syndrome |
Kimberly N. Shudofsky, Paddy K. C. Janssen, N. Foudraine, Jos L. M. L. Noble |
| 17 |
[GO] |
2021―Aug―05 |
The Risk of SARS-COV-2 Infection and Covid-19 Severity Associated with The Exposure to Non-Steroidal Anti-Inflammatory Drugs: Systematic Review and Meta-Analysis |
Luísa Prada, Catarina D. Santos, Rita A. Baião, João Costa, Joaquim J. Ferreira, Daniel Caldeira |
| 18 |
[GO] |
2021―Jul―01 |
Corticosteroids in COVID-19: We should be mindful of its acute toxicities |
Mitesh Karn, Sapana Yonghang, Sadikshya Ghimire |
| 19 |
[GO] |
2021―Jun―22 |
Therapeutic Application of Corticosteroids in COVID-19: A Focus on Optimum Dose and Duration of Therapy |
Sajad Khiali, Taher Entezari-Maleki |
| 20 |
[GO] |
2021―Apr―28 |
Pharmacological Predictors of Morbidity and Mortality in COVID-19 |
Christopher Oddy, James McCaul, Polly Keeling, Jonathan Allington, Dhanuja Senn, Neesha Soni, Hannah Morrison, Ruwani Mawella, Thomas Samuel, John Dixon |
| 21 |
[GO] |
2021―Apr―19 |
Baricitinib: From Rheumatoid Arthritis to COVID-19
5 |
Sara Assadiasl, Yousef Fatahi, Banafsheh Mosharmovahed, Bahareh Mohebbi, Mohammad Hossein Nicknam |
| 22 |
[GO] |
2021―Apr―07 |
Clinical Equipoise in COVID-19 Vaccine Candidates Trials |
Rafael Dal-Ré |
| 23 |
[GO] |
2021―Feb―26 |
The Interplay between the Immune System, the Renin Angiotensin Aldosterone System (RAAS) and RAAS Inhibitors May Modulate the Outcome of COVID-19: A Systematic Review |
Hiba Naveed, Abdallah Elshafeey, Dana Al-Ali, Emmad Janjua, Areej Nauman, Hussam Kawas, Ridhima Kaul, Arwa Saed Aldien, Mohamed B. Elshazly, Dalia Zakaria |
| 24 |
[GO] |
2021―Jan―29 |
Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review |
Elnaz Khani, Sajad Khiali, Taher Entezari-Maleki |
| 25 |
[GO] |
2021―Jan―21 |
AAMC Discusses Monoclonal Antibody Therapeutics for SARS-CoV-2 Infection |
Vera S. Donnenberg |
| 26 |
[GO] |
2020―Dez―18 |
Amantadine for COVID-19 |
Paweł Grieb, Maciej Świątkiewicz, Katarzyna Prus, Konrad Rejdak |
| 27 |
[GO] |
2020―Dez―04 |
Science and Evidence-based Review and Approval of COVID-19 Vaccines: A Statement of Support for the U.S. FDA |
Sudhakar M. Pai, Ahmed A. Othman, Lorraine Rusch, Joanna C. Masters, Douglas Greene, Mark Rogge, Jean-Michel Gries, William Clementi, Parag Kumar, Islam Younis, Ahmed Hamed Salem, Bruce Gaynes, Gina Pastino, Hartmut Derendorf |
| 28 |
[GO] |
2020―Nov―21 |
Antiretrovirals for prophylaxis against COVID-19; a comprehensive literature review |
Golbarg Alavian, Kasra Kolahdouzan, Masoud Mortezazadeh, Zahra Sadat Torabi |
| 29 |
[GO] |
2020―Nov―12 |
Treatment with Tocilizumab for Patients with Covid-19 Infections: A Case-series Study |
Yoonsun Mo, Obed Adarkwah, John Zeibeq, Evgeny Pinelis, Jose Orsini, James Gasperino |
| 30 |
[GO] |
2020―Sep―04 |
Empiric therapeutic anticoagulation and mortality in critically ill patients with respiratory failure from SARS-CoV-2: A retrospective cohort study |
John Ferguson, Stacy Volk, Thomas Vondracek, John Flanigan, Andrew Chernaik |
| 31 |
[GO] |
2020―Aug―11 |
Immunomodulatory Therapeutic Proteins in COVID-19: Current Clinical Development and Clinical Pharmacology Considerations |
Ping Ji, Jianmeng Chen, Amit Golding, Nikolay P. Nikolov, Bhawana Saluja, Yunzhao R. Ren, Chandrahas Sahajwalla |
| 32 |
[GO] |
2020―Jul―01 |
Overmedication in COVID-19 context: a report from Peru |
Raisa N. Martinez-Rivera, Alvaro Taype-Rondan |
| 33 |
[GO] |
2020―Jun―24 |
Clinical pharmacology considerations for developing small molecule treatments for COVID-19 |
Priya Brunsdon, Bhawana Saluja, Chandrahas Sahajwalla |
| 34 |
[GO] |
2020―Jun―19 |
A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome |
Sajad Khiali, Elnaz Khani, Taher Entezari-Maleki |
| 35 |
[GO] |
2020―Jun―14 |
Critical Need for Implementation of Clinical Pharmacology Principles in Developing Drugs for the Treatment or Prevention of COVID-19 |
Gina Pastino |
| 36 |
[GO] |
2020―Jun―12 |
Why your Patients’ Believing Hydroxychloroquine and Chloroquine are 90% Effective for COVID-19 is 100% Dangerous |
C. Michael White, Adrian V. Hernandez |
| 37 |
[GO] |
2020―Jun―08 |
Colchicine and COVID-19 |
Pablo Corral, Gonzalo Corral, Rafael Diaz |
| 38 |
[GO] |
2020―Mai―29 |
A Comprehensive Updated Review on SARS-CoV-2 and COVID-19 |
Yunzhao R. Ren, Amit Golding, Alfred Sorbello, Ping Ji, Jianmeng Chen, Saluja Bhawana, Kimberly Witzmann, Vikram Arya, Kellie S. Reynolds, Su-Young Choi, Nikolay Nikolov, Chandrahas Sahajwalla |
| 39 |
[GO] |
2020―Mai―29 |
Evaluation of potential therapeutic options for COVID-19 |
Daren Austin, Malek Okour |
| 40 |
[GO] |
2020―Mai―23 |
Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19? |
Somayyeh Nasiripour, Farhad Zamani, Maryam Farasatinasab |
| 41 |
[GO] |
2020―Mai―22 |
Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin |
Luca Gallelli, Leiming Zhang, Tian Wang, Fenghua Fu |
| 42 |
[GO] |
2020―Mai―21 |
Intuitive Global Insight Into COVID-19 Clinical Research Activities-The “COVID-19 Map of Hope” |
Markus Ries, Konstantin Mechler, Donna L. Smith, Benjamin Herfort, Johannes Visintini, Amon Veiga Santana, Alexander Zipf, Sven Lautenbach |
| 43 |
[GO] |
2020―Mai―21 |
TMPRSS2: Potential Biomarker for COVID-19 Outcomes |
Jonathan D. Strope, Cindy H. Chau, PharmD, William D. Figg |
| 44 |
[GO] |
2020―Mai―20 |
Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes? |
Bruno Mégarbane, Jean-Michel Scherrmann |
